A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, active and placebo controlled, 4 way crossover study in
patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20
mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.